IDEAYA Biosciences (IDYA) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.

9 brokerages have issued 1-year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.40 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.

IDEAYA Biosciences' stock was trading at $18.17 on January 1st, 2023. Since then, IDYA shares have increased by 32.7% and is now trading at $24.11.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our IDYA earnings forecast.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.03. The company had revenue of $7.90 million for the quarter, compared to analysts' expectations of $5.38 million. IDEAYA Biosciences had a negative net margin of 143.90% and a negative trailing twelve-month return on equity of 20.67%. The company's quarterly revenue was up 97.5% on a year-over-year basis.

ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

(IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Logos Global Management LP (7.44%), BlackRock Inc. (7.33%), BVF Inc. IL (4.29%), State Street Corp (3.69%), Price T Rowe Associates Inc. MD (3.03%) and Dimensional Fund Advisors LP (2.14%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDYA stock can currently be purchased for approximately $24.11.

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.38 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.